Royalty Pharma plc

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, VRTX has a market cap of 121.1B. Regarding current trading prices, RPRX is priced at $45.11, while VRTX trades at $469.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas VRTX's P/E ratio is 31.11. In terms of profitability, RPRX's ROE is +0.12%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, RPRX is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check VRTX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, REGN has a market cap of 81B. Regarding current trading prices, RPRX is priced at $45.11, while REGN trades at $782.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas REGN's P/E ratio is 18.78. In terms of profitability, RPRX's ROE is +0.12%, compared to REGN's ROE of +0.15%. Regarding short-term risk, RPRX is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check REGN's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, RPRX is priced at $45.11, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas VRNA's P/E ratio is -102.80. In terms of profitability, RPRX's ROE is +0.12%, compared to VRNA's ROE of -0.30%. Regarding short-term risk, RPRX is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check VRNA's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, ARGX has a market cap of 52.3B. Regarding current trading prices, RPRX is priced at $45.11, while ARGX trades at $847.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas ARGX's P/E ratio is 36.06. In terms of profitability, RPRX's ROE is +0.12%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, RPRX is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check ARGX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, ALNY has a market cap of 44.6B. Regarding current trading prices, RPRX is priced at $45.11, while ALNY trades at $339.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas ALNY's P/E ratio is 144.29. In terms of profitability, RPRX's ROE is +0.12%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, RPRX is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check ALNY's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, RPRX is priced at $45.11, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas SGEN's P/E ratio is -57.19. In terms of profitability, RPRX's ROE is +0.12%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, RPRX is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check SGEN's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, INSM has a market cap of 35.2B. Regarding current trading prices, RPRX is priced at $45.11, while INSM trades at $161.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas INSM's P/E ratio is -26.68. In terms of profitability, RPRX's ROE is +0.12%, compared to INSM's ROE of -1.68%. Regarding short-term risk, RPRX is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check INSM's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, BNTX has a market cap of 26.5B. Regarding current trading prices, RPRX is priced at $45.11, while BNTX trades at $110.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas BNTX's P/E ratio is -38.78. In terms of profitability, RPRX's ROE is +0.12%, compared to BNTX's ROE of -0.03%. Regarding short-term risk, RPRX is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check BNTX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, UTHR has a market cap of 21.4B. Regarding current trading prices, RPRX is priced at $45.11, while UTHR trades at $480.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas UTHR's P/E ratio is 17.94. In terms of profitability, RPRX's ROE is +0.12%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, RPRX is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check UTHR's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, RPRX is priced at $45.11, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas BGNE's P/E ratio is -22.55. In terms of profitability, RPRX's ROE is +0.12%, compared to BGNE's ROE of +0.02%. Regarding short-term risk, RPRX is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check BGNE's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, INCY has a market cap of 20.2B. Regarding current trading prices, RPRX is priced at $45.11, while INCY trades at $101.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas INCY's P/E ratio is 15.81. In terms of profitability, RPRX's ROE is +0.12%, compared to INCY's ROE of +0.29%. Regarding short-term risk, RPRX is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check INCY's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, RVMD has a market cap of 19.7B. Regarding current trading prices, RPRX is priced at $45.11, while RVMD trades at $102.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas RVMD's P/E ratio is -19.62. In terms of profitability, RPRX's ROE is +0.12%, compared to RVMD's ROE of -0.49%. Regarding short-term risk, RPRX is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check RVMD's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, MRNA has a market cap of 19.5B. Regarding current trading prices, RPRX is priced at $45.11, while MRNA trades at $49.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas MRNA's P/E ratio is -6.87. In terms of profitability, RPRX's ROE is +0.12%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, RPRX is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check MRNA's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, ROIV has a market cap of 19.4B. Regarding current trading prices, RPRX is priced at $45.11, while ROIV trades at $27.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas ROIV's P/E ratio is -23.21. In terms of profitability, RPRX's ROE is +0.12%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, RPRX is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check ROIV's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, RPRX is priced at $45.11, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, RPRX is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check DNA-WT's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, GMAB has a market cap of 18B. Regarding current trading prices, RPRX is priced at $45.11, while GMAB trades at $28.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas GMAB's P/E ratio is 12.96. In terms of profitability, RPRX's ROE is +0.12%, compared to GMAB's ROE of +0.24%. Regarding short-term risk, RPRX is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check GMAB's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, ASND has a market cap of 13.8B. Regarding current trading prices, RPRX is priced at $45.11, while ASND trades at $230.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas ASND's P/E ratio is -50.34. In terms of profitability, RPRX's ROE is +0.12%, compared to ASND's ROE of +1.28%. Regarding short-term risk, RPRX is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check ASND's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, IONS has a market cap of 13.5B. Regarding current trading prices, RPRX is priced at $45.11, while IONS trades at $83.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas IONS's P/E ratio is -51.65. In terms of profitability, RPRX's ROE is +0.12%, compared to IONS's ROE of -0.44%. Regarding short-term risk, RPRX is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check IONS's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, BBIO has a market cap of 13.1B. Regarding current trading prices, RPRX is priced at $45.11, while BBIO trades at $70.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas BBIO's P/E ratio is -16.19. In terms of profitability, RPRX's ROE is +0.12%, compared to BBIO's ROE of +0.47%. Regarding short-term risk, RPRX is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check BBIO's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, RPRX is priced at $45.11, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas KRTX's P/E ratio is -28.09. In terms of profitability, RPRX's ROE is +0.12%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, RPRX is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check KRTX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, BMRN has a market cap of 12.3B. Regarding current trading prices, RPRX is priced at $45.11, while BMRN trades at $63.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas BMRN's P/E ratio is 23.82. In terms of profitability, RPRX's ROE is +0.12%, compared to BMRN's ROE of +0.00%. Regarding short-term risk, RPRX is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check BMRN's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, SMMT has a market cap of 11.9B. Regarding current trading prices, RPRX is priced at $45.11, while SMMT trades at $15.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas SMMT's P/E ratio is -12.75. In terms of profitability, RPRX's ROE is +0.12%, compared to SMMT's ROE of -3.11%. Regarding short-term risk, RPRX is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check SMMT's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, EXEL has a market cap of 11.7B. Regarding current trading prices, RPRX is priced at $45.11, while EXEL trades at $44.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas EXEL's P/E ratio is 15.69. In terms of profitability, RPRX's ROE is +0.12%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, RPRX is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check EXEL's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, RNA has a market cap of 11.3B. Regarding current trading prices, RPRX is priced at $45.11, while RNA trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas RNA's P/E ratio is -17.39. In terms of profitability, RPRX's ROE is +0.12%, compared to RNA's ROE of -0.38%. Regarding short-term risk, RPRX is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check RNA's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, JAZZ has a market cap of 10.5B. Regarding current trading prices, RPRX is priced at $45.11, while JAZZ trades at $169.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas JAZZ's P/E ratio is -27.95. In terms of profitability, RPRX's ROE is +0.12%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, RPRX is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check JAZZ's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, MDGL has a market cap of 9.9B. Regarding current trading prices, RPRX is priced at $45.11, while MDGL trades at $436.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas MDGL's P/E ratio is -33.64. In terms of profitability, RPRX's ROE is +0.12%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, RPRX is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check MDGL's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, RPRX is priced at $45.11, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas RXDX's P/E ratio is -56.47. In terms of profitability, RPRX's ROE is +0.12%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, RPRX is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check RXDX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, AXSM has a market cap of 9.3B. Regarding current trading prices, RPRX is priced at $45.11, while AXSM trades at $186.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas AXSM's P/E ratio is -39.01. In terms of profitability, RPRX's ROE is +0.12%, compared to AXSM's ROE of -3.57%. Regarding short-term risk, RPRX is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check AXSM's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, TECH has a market cap of 9B. Regarding current trading prices, RPRX is priced at $45.11, while TECH trades at $58.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas TECH's P/E ratio is 108.53. In terms of profitability, RPRX's ROE is +0.12%, compared to TECH's ROE of +0.04%. Regarding short-term risk, RPRX is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check TECH's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, ARWR has a market cap of 8.9B. Regarding current trading prices, RPRX is priced at $45.11, while ARWR trades at $63.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas ARWR's P/E ratio is 39.74. In terms of profitability, RPRX's ROE is +0.12%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, RPRX is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check ARWR's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, RPRX is priced at $45.11, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas IMGN's P/E ratio is -111.55. In terms of profitability, RPRX's ROE is +0.12%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, RPRX is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check IMGN's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, IBRX has a market cap of 8.6B. Regarding current trading prices, RPRX is priced at $45.11, while IBRX trades at $8.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas IBRX's P/E ratio is -21.22. In terms of profitability, RPRX's ROE is +0.12%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, RPRX is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check IBRX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, ABVX has a market cap of 8.5B. Regarding current trading prices, RPRX is priced at $45.11, while ABVX trades at $130.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas ABVX's P/E ratio is -24.14. In terms of profitability, RPRX's ROE is +0.12%, compared to ABVX's ROE of +50.78%. Regarding short-term risk, RPRX is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check ABVX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, RPRX is priced at $45.11, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas BPMC's P/E ratio is -51.58. In terms of profitability, RPRX's ROE is +0.12%, compared to BPMC's ROE of -0.33%. Regarding short-term risk, RPRX is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check BPMC's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, HALO has a market cap of 8.3B. Regarding current trading prices, RPRX is priced at $45.11, while HALO trades at $72.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas HALO's P/E ratio is 15.20. In terms of profitability, RPRX's ROE is +0.12%, compared to HALO's ROE of +0.93%. Regarding short-term risk, RPRX is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check HALO's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, CYTK has a market cap of 8.3B. Regarding current trading prices, RPRX is priced at $45.11, while CYTK trades at $67.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas CYTK's P/E ratio is -10.78. In terms of profitability, RPRX's ROE is +0.12%, compared to CYTK's ROE of +2.33%. Regarding short-term risk, RPRX is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check CYTK's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, PCVX has a market cap of 8.3B. Regarding current trading prices, RPRX is priced at $45.11, while PCVX trades at $57.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas PCVX's P/E ratio is -12.06. In terms of profitability, RPRX's ROE is +0.12%, compared to PCVX's ROE of -0.21%. Regarding short-term risk, RPRX is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check PCVX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, RPRX is priced at $45.11, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas CERE's P/E ratio is -16.47. In terms of profitability, RPRX's ROE is +0.12%, compared to CERE's ROE of -0.72%. Regarding short-term risk, RPRX is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check CERE's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, KRYS has a market cap of 7.6B. Regarding current trading prices, RPRX is priced at $45.11, while KRYS trades at $262.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas KRYS's P/E ratio is 42.23. In terms of profitability, RPRX's ROE is +0.12%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, RPRX is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check KRYS's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, RPRX is priced at $45.11, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas MTSR's P/E ratio is -23.58. In terms of profitability, RPRX's ROE is +0.12%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, RPRX is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check MTSR's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, NUVL has a market cap of 7.3B. Regarding current trading prices, RPRX is priced at $45.11, while NUVL trades at $104.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas NUVL's P/E ratio is -18.86. In terms of profitability, RPRX's ROE is +0.12%, compared to NUVL's ROE of -0.39%. Regarding short-term risk, RPRX is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check NUVL's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, PRAX has a market cap of 7.1B. Regarding current trading prices, RPRX is priced at $45.11, while PRAX trades at $331.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas PRAX's P/E ratio is -25.87. In terms of profitability, RPRX's ROE is +0.12%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, RPRX is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check PRAX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, KYMR has a market cap of 6.9B. Regarding current trading prices, RPRX is priced at $45.11, while KYMR trades at $86.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas KYMR's P/E ratio is -24.28. In terms of profitability, RPRX's ROE is +0.12%, compared to KYMR's ROE of -0.33%. Regarding short-term risk, RPRX is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check KYMR's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, RPRX is priced at $45.11, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas MRUS's P/E ratio is -17.05. In terms of profitability, RPRX's ROE is +0.12%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, RPRX is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check MRUS's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, RYTM has a market cap of 6.7B. Regarding current trading prices, RPRX is priced at $45.11, while RYTM trades at $103.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas RYTM's P/E ratio is -32.19. In terms of profitability, RPRX's ROE is +0.12%, compared to RYTM's ROE of -1.66%. Regarding short-term risk, RPRX is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check RYTM's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, RPRX is priced at $45.11, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas RETA's P/E ratio is -66.29. In terms of profitability, RPRX's ROE is +0.12%, compared to RETA's ROE of +0.47%. Regarding short-term risk, RPRX is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check RETA's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, BLTE has a market cap of 6.3B. Regarding current trading prices, RPRX is priced at $45.11, while BLTE trades at $179.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas BLTE's P/E ratio is -94.24. In terms of profitability, RPRX's ROE is +0.12%, compared to BLTE's ROE of -0.34%. Regarding short-term risk, RPRX is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check BLTE's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, COGT has a market cap of 5.7B. Regarding current trading prices, RPRX is priced at $45.11, while COGT trades at $38.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas COGT's P/E ratio is -18.21. In terms of profitability, RPRX's ROE is +0.12%, compared to COGT's ROE of -1.00%. Regarding short-term risk, RPRX is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check COGT's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, PTCT has a market cap of 5.7B. Regarding current trading prices, RPRX is priced at $45.11, while PTCT trades at $69.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas PTCT's P/E ratio is 8.21. In terms of profitability, RPRX's ROE is +0.12%, compared to PTCT's ROE of -1.83%. Regarding short-term risk, RPRX is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check PTCT's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, RPRX is priced at $45.11, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas CDTX's P/E ratio is -19.77. In terms of profitability, RPRX's ROE is +0.12%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, RPRX is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check CDTX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, RPRX is priced at $45.11, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, RPRX's ROE is +0.12%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, RPRX is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check ABCM's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, RPRX is priced at $45.11, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas ISEE's P/E ratio is -22.44. In terms of profitability, RPRX's ROE is +0.12%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, RPRX is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check ISEE's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, CAI has a market cap of 5.5B. Regarding current trading prices, RPRX is priced at $45.11, while CAI trades at $20.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas CAI's P/E ratio is -5.55. In terms of profitability, RPRX's ROE is +0.12%, compared to CAI's ROE of +0.27%. Regarding short-term risk, RPRX is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check CAI's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, MIRM has a market cap of 5.4B. Regarding current trading prices, RPRX is priced at $45.11, while MIRM trades at $105.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas MIRM's P/E ratio is -125.19. In terms of profitability, RPRX's ROE is +0.12%, compared to MIRM's ROE of -0.16%. Regarding short-term risk, RPRX is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check MIRM's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, IMVT has a market cap of 5.4B. Regarding current trading prices, RPRX is priced at $45.11, while IMVT trades at $26.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas IMVT's P/E ratio is -9.96. In terms of profitability, RPRX's ROE is +0.12%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, RPRX is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check IMVT's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, ALKS has a market cap of 5.3B. Regarding current trading prices, RPRX is priced at $45.11, while ALKS trades at $32.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas ALKS's P/E ratio is 16.27. In terms of profitability, RPRX's ROE is +0.12%, compared to ALKS's ROE of +0.21%. Regarding short-term risk, RPRX is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check ALKS's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, RPRX is priced at $45.11, while FBIOX trades at $25.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas FBIOX's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, RPRX is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check FBIOX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, PTGX has a market cap of 5.2B. Regarding current trading prices, RPRX is priced at $45.11, while PTGX trades at $83.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas PTGX's P/E ratio is 125.39. In terms of profitability, RPRX's ROE is +0.12%, compared to PTGX's ROE of +0.07%. Regarding short-term risk, RPRX is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check PTGX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, CRSP has a market cap of 5.1B. Regarding current trading prices, RPRX is priced at $45.11, while CRSP trades at $54.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas CRSP's P/E ratio is -8.26. In terms of profitability, RPRX's ROE is +0.12%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, RPRX is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check CRSP's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, SRRK has a market cap of 4.9B. Regarding current trading prices, RPRX is priced at $45.11, while SRRK trades at $47.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas SRRK's P/E ratio is -15.24. In terms of profitability, RPRX's ROE is +0.12%, compared to SRRK's ROE of -1.22%. Regarding short-term risk, RPRX is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check SRRK's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, CELC has a market cap of 4.8B. Regarding current trading prices, RPRX is priced at $45.11, while CELC trades at $106.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas CELC's P/E ratio is -28.87. In terms of profitability, RPRX's ROE is +0.12%, compared to CELC's ROE of -1.79%. Regarding short-term risk, RPRX is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check CELC's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, TGTX has a market cap of 4.7B. Regarding current trading prices, RPRX is priced at $45.11, while TGTX trades at $29.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas TGTX's P/E ratio is 10.58. In terms of profitability, RPRX's ROE is +0.12%, compared to TGTX's ROE of +1.33%. Regarding short-term risk, RPRX is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check TGTX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, CGON has a market cap of 4.6B. Regarding current trading prices, RPRX is priced at $45.11, while CGON trades at $56.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas CGON's P/E ratio is -28.11. In terms of profitability, RPRX's ROE is +0.12%, compared to CGON's ROE of -0.22%. Regarding short-term risk, RPRX is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check CGON's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, RPRX is priced at $45.11, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas AKRO's P/E ratio is -14.57. In terms of profitability, RPRX's ROE is +0.12%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, RPRX is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check AKRO's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, RPRX is priced at $45.11, while FOLD trades at $14.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas FOLD's P/E ratio is -358.50. In terms of profitability, RPRX's ROE is +0.12%, compared to FOLD's ROE of -0.07%. Regarding short-term risk, RPRX is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check FOLD's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, RPRX is priced at $45.11, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas ALPN's P/E ratio is -101.52. In terms of profitability, RPRX's ROE is +0.12%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, RPRX is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check ALPN's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, CRNX has a market cap of 4.5B. Regarding current trading prices, RPRX is priced at $45.11, while CRNX trades at $44.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas CRNX's P/E ratio is -9.59. In terms of profitability, RPRX's ROE is +0.12%, compared to CRNX's ROE of -0.35%. Regarding short-term risk, RPRX is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check CRNX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, RPRX is priced at $45.11, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas OPT's P/E ratio is -1.52. In terms of profitability, RPRX's ROE is +0.12%, compared to OPT's ROE of +0.88%. Regarding short-term risk, RPRX is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check OPT's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, RPRX is priced at $45.11, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas MRTX's P/E ratio is -4.82. In terms of profitability, RPRX's ROE is +0.12%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, RPRX is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check MRTX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, ACAD has a market cap of 4.1B. Regarding current trading prices, RPRX is priced at $45.11, while ACAD trades at $24.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas ACAD's P/E ratio is 15.48. In terms of profitability, RPRX's ROE is +0.12%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, RPRX is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check ACAD's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, NAMS has a market cap of 4B. Regarding current trading prices, RPRX is priced at $45.11, while NAMS trades at $34.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas NAMS's P/E ratio is -17.44. In terms of profitability, RPRX's ROE is +0.12%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, RPRX is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check NAMS's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, ERAS has a market cap of 3.9B. Regarding current trading prices, RPRX is priced at $45.11, while ERAS trades at $12.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas ERAS's P/E ratio is -29.16. In terms of profitability, RPRX's ROE is +0.12%, compared to ERAS's ROE of -0.33%. Regarding short-term risk, RPRX is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check ERAS's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, ADMA has a market cap of 3.8B. Regarding current trading prices, RPRX is priced at $45.11, while ADMA trades at $16.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas ADMA's P/E ratio is 18.72. In terms of profitability, RPRX's ROE is +0.12%, compared to ADMA's ROE of +0.54%. Regarding short-term risk, RPRX is less volatile compared to ADMA. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check ADMA's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, GPCR has a market cap of 3.8B. Regarding current trading prices, RPRX is priced at $45.11, while GPCR trades at $67.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas GPCR's P/E ratio is -18.18. In terms of profitability, RPRX's ROE is +0.12%, compared to GPCR's ROE of -0.26%. Regarding short-term risk, RPRX is less volatile compared to GPCR. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check GPCR's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, RPRX is priced at $45.11, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas RYZB's P/E ratio is -57.86. In terms of profitability, RPRX's ROE is +0.12%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, RPRX is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check RYZB's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, APGE has a market cap of 3.8B. Regarding current trading prices, RPRX is priced at $45.11, while APGE trades at $68.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas APGE's P/E ratio is -15.61. In terms of profitability, RPRX's ROE is +0.12%, compared to APGE's ROE of -0.39%. Regarding short-term risk, RPRX is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check APGE's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, RPRX is priced at $45.11, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas CBAY's P/E ratio is -32.81. In terms of profitability, RPRX's ROE is +0.12%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, RPRX is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check CBAY's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, ACLX has a market cap of 3.7B. Regarding current trading prices, RPRX is priced at $45.11, while ACLX trades at $66.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas ACLX's P/E ratio is -16.31. In terms of profitability, RPRX's ROE is +0.12%, compared to ACLX's ROE of -0.51%. Regarding short-term risk, RPRX is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check ACLX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, CORT has a market cap of 3.7B. Regarding current trading prices, RPRX is priced at $45.11, while CORT trades at $34.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas CORT's P/E ratio is 40.02. In terms of profitability, RPRX's ROE is +0.12%, compared to CORT's ROE of +0.16%. Regarding short-term risk, RPRX is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check CORT's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, LGND has a market cap of 3.6B. Regarding current trading prices, RPRX is priced at $45.11, while LGND trades at $186.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas LGND's P/E ratio is 81.41. In terms of profitability, RPRX's ROE is +0.12%, compared to LGND's ROE of +0.06%. Regarding short-term risk, RPRX is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check LGND's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, VKTX has a market cap of 3.6B. Regarding current trading prices, RPRX is priced at $45.11, while VKTX trades at $31.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas VKTX's P/E ratio is -9.73. In terms of profitability, RPRX's ROE is +0.12%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, RPRX is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check VKTX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, RPRX is priced at $45.11, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas SWTX's P/E ratio is -13.78. In terms of profitability, RPRX's ROE is +0.12%, compared to SWTX's ROE of -0.45%. Regarding short-term risk, RPRX is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check SWTX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, TERN has a market cap of 3.5B. Regarding current trading prices, RPRX is priced at $45.11, while TERN trades at $39.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas TERN's P/E ratio is -38.46. In terms of profitability, RPRX's ROE is +0.12%, compared to TERN's ROE of -0.30%. Regarding short-term risk, RPRX is less volatile compared to TERN. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check TERN's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, KNSA has a market cap of 3.5B. Regarding current trading prices, RPRX is priced at $45.11, while KNSA trades at $47.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas KNSA's P/E ratio is 106.16. In terms of profitability, RPRX's ROE is +0.12%, compared to KNSA's ROE of +0.07%. Regarding short-term risk, RPRX is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check KNSA's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, CNTA has a market cap of 3.3B. Regarding current trading prices, RPRX is priced at $45.11, while CNTA trades at $24.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas CNTA's P/E ratio is -12.96. In terms of profitability, RPRX's ROE is +0.12%, compared to CNTA's ROE of -0.68%. Regarding short-term risk, RPRX is less volatile compared to CNTA. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check CNTA's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, XENE has a market cap of 3.3B. Regarding current trading prices, RPRX is priced at $45.11, while XENE trades at $43.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas XENE's P/E ratio is -10.86. In terms of profitability, RPRX's ROE is +0.12%, compared to XENE's ROE of -0.46%. Regarding short-term risk, RPRX is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check XENE's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, DNLI has a market cap of 3.2B. Regarding current trading prices, RPRX is priced at $45.11, while DNLI trades at $20.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas DNLI's P/E ratio is -6.91. In terms of profitability, RPRX's ROE is +0.12%, compared to DNLI's ROE of -0.46%. Regarding short-term risk, RPRX is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check DNLI's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, ARQT has a market cap of 3.1B. Regarding current trading prices, RPRX is priced at $45.11, while ARQT trades at $27.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas ARQT's P/E ratio is -74.75. In terms of profitability, RPRX's ROE is +0.12%, compared to ARQT's ROE of -0.30%. Regarding short-term risk, RPRX is less volatile compared to ARQT. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check ARQT's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, EWTX has a market cap of 3.1B. Regarding current trading prices, RPRX is priced at $45.11, while EWTX trades at $29.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas EWTX's P/E ratio is -18.67. In terms of profitability, RPRX's ROE is +0.12%, compared to EWTX's ROE of -0.31%. Regarding short-term risk, RPRX is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check EWTX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, CPRX has a market cap of 3B. Regarding current trading prices, RPRX is priced at $45.11, while CPRX trades at $24.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas CPRX's P/E ratio is 14.21. In terms of profitability, RPRX's ROE is +0.12%, compared to CPRX's ROE of +0.26%. Regarding short-term risk, RPRX is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check CPRX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, NAMSW has a market cap of 3B. Regarding current trading prices, RPRX is priced at $45.11, while NAMSW trades at $25.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas NAMSW's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to NAMSW's ROE of -0.27%. Regarding short-term risk, RPRX is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check NAMSW's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, VERA has a market cap of 2.9B. Regarding current trading prices, RPRX is priced at $45.11, while VERA trades at $42.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas VERA's P/E ratio is -10.16. In terms of profitability, RPRX's ROE is +0.12%, compared to VERA's ROE of -0.51%. Regarding short-term risk, RPRX is less volatile compared to VERA. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check VERA's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, LQDA has a market cap of 2.9B. Regarding current trading prices, RPRX is priced at $45.11, while LQDA trades at $35.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas LQDA's P/E ratio is -23.01. In terms of profitability, RPRX's ROE is +0.12%, compared to LQDA's ROE of -2.97%. Regarding short-term risk, RPRX is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check LQDA's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, ALMS has a market cap of 2.9B. Regarding current trading prices, RPRX is priced at $45.11, while ALMS trades at $29.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas ALMS's P/E ratio is -13.01. In terms of profitability, RPRX's ROE is +0.12%, compared to ALMS's ROE of -0.76%. Regarding short-term risk, RPRX is less volatile compared to ALMS. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check ALMS's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, RPRX is priced at $45.11, while MORF trades at $56.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas MORF's P/E ratio is -14.88. In terms of profitability, RPRX's ROE is +0.12%, compared to MORF's ROE of -0.29%. Regarding short-term risk, RPRX is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check MORF's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, RPRX is priced at $45.11, while MOR trades at $18.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas MOR's P/E ratio is -12.64. In terms of profitability, RPRX's ROE is +0.12%, compared to MOR's ROE of -1.84%. Regarding short-term risk, RPRX is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check MOR's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, TARS has a market cap of 2.8B. Regarding current trading prices, RPRX is priced at $45.11, while TARS trades at $65.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas TARS's P/E ratio is -33.47. In terms of profitability, RPRX's ROE is +0.12%, compared to TARS's ROE of -0.26%. Regarding short-term risk, RPRX is less volatile compared to TARS. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check TARS's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, APLS has a market cap of 2.8B. Regarding current trading prices, RPRX is priced at $45.11, while APLS trades at $22.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas APLS's P/E ratio is 61.89. In terms of profitability, RPRX's ROE is +0.12%, compared to APLS's ROE of +0.19%. Regarding short-term risk, RPRX is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check APLS's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 19.3B. In comparison, VCYT has a market cap of 2.8B. Regarding current trading prices, RPRX is priced at $45.11, while VCYT trades at $36.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 25.35, whereas VCYT's P/E ratio is 93.76. In terms of profitability, RPRX's ROE is +0.12%, compared to VCYT's ROE of +0.03%. Regarding short-term risk, RPRX is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check VCYT's competition here